GCM
PRQR icon

Graham Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Graham Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-91,553
Closed -$148K – 1445
2026
Q1 		$148K Buy
+91,553
New +$150K ﹤0.01% 997

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Graham Capital Management's PRQR Position: Q2 2026 in Review

Graham Capital Management sold out of ProQR Therapeutics (PRQR) in Q2 2026, closing a stake of 91,553 shares — an estimated $148K sold.

Graham Capital Management first reported a position in PRQR in Q1 2026 and held it in 1 quarter. The position peaked at $148K in Q1 2026. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Graham Capital Management reported no remaining ProQR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 91,553 ProQR Therapeutics shares in Q2 2026, an estimated $148K.
  • Graham Capital Management first reported a position in ProQR Therapeutics in Q1 2026 and held it in 1 quarter.
  • Graham Capital Management's ProQR Therapeutics position peaked at $148K in Q1 2026.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.